Arcus Biosciences Inc. (RCUS)
NYSE · Healthcare
Arcus Biosciences Inc. Shareholder Equity 2017–2025
Arcus Biosciences Inc. annual shareholder equity history from 2017 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Arcus Biosciences Inc. shareholder equity as of December 31, 2025: 631.0M, a 30.10% increase year-over-year.
- Arcus Biosciences Inc. shareholder equity for 2025 were 631.0M, a 30.10% increase from 2024.
- Arcus Biosciences Inc. shareholder equity for 2024 were 485.0M, a 4.98% increase from 2023.
- Arcus Biosciences Inc. shareholder equity for 2023 were 462.0M, a 29.68% decrease from 2022.
- Arcus Biosciences Inc. shareholder equity for 2022 were 657.0M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Arcus Biosciences Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $631 |
| 2024 | $485 |
| 2023 | $462 |
| 2022 | $657 |
| 2021 | $842 |
| 2020 | $502 |
| 2019 | $164 |
| 2018 | $235 |
| 2017 | $-72 |
Arcus Biosciences Inc. Shareholder Equity — FAQ
Arcus Biosciences Inc. (RCUS) shareholder equity over the last 9 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see RCUS's shareholder equity history?
The chart and table above show Arcus Biosciences Inc.'s shareholder equity by year and by quarter, including the growth rate.